Macrophage migration inhibitory factor -173 polymorphism and risk of coronary alterations in children with Kawasaki disease

Clin Exp Rheumatol. 2009 Nov-Dec;27(6):1026-30.

Abstract

Objective: To investigate the possible relationship between MIF -173 polymorphism and susceptibility to, and severity of, Kawasaki disease (KD) in a cohort of Italian patients.

Methods: Sixty-nine patients (43 F, 26 M, median age 29 months, range 3-135 months) with KD and 60 sex-matched healthy caucasian children were genotyped for MIF-173. Typing of the MIF gene -173 G/C was performed by PCR and restriction fragment length polymorphism.

Results: Eight out of 69 (12%) KD children were non-responders: 7 required an additional IVIG infusion, while 1 received 2 IVIG infusions and then steroid administration. 9/69 (13%) KD children developed coronary artery abnormalities (CAA) during the second to fourth week of disease, and 4 of them required an additional IVIG infusion. MIF genotyping did not show significant differences between patients and controls. KD patients carrying a MIF -173*C allele developed CAA more frequently than those without MIF- (7/9 77.8% vs. 16/60 26.7%, OR 9.6, 95% CI 1.80-21.2, p<0.005). Non-responders to a single IVIG infusion carried the MIF -173*C allele more frequently than responders (6/8 = 75% vs. 17/61 = 28%, OR 5.1, 95% CI 1.42-22.31 p<0.014). In multiple regression analysis, KD patients carrying a MIF -173*C allele were found to have an increased risk of coronary involvement (OR 7.7, 95% CI 1.36-16.1, p=0.021).

Conclusions: We showed that children carrying the MIF polymorphism -173*C had a higher percentage of CAA. A potential relationship between a MIF polymorphism and risk of CAA in KD might be considered.

MeSH terms

  • Alleles
  • Child
  • Child, Preschool
  • Coronary Vessel Anomalies / genetics*
  • Female
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Infant
  • Italy
  • Macrophage Migration-Inhibitory Factors / genetics*
  • Male
  • Mucocutaneous Lymph Node Syndrome / genetics*
  • Mucocutaneous Lymph Node Syndrome / therapy
  • Mutation / genetics
  • Polymerase Chain Reaction
  • Polymorphism, Single Nucleotide / genetics*
  • Risk Factors
  • Severity of Illness Index

Substances

  • Immunoglobulins, Intravenous
  • Macrophage Migration-Inhibitory Factors